CD22 and hairy cell leukemia: More recently, another CD22-targeted ADC, Moxetumomab pasudotox (Lumoxit), became the first immunotoxin to be globally approved for managing relapsed or refractory hairy cell leukemia (HCL) but was permanently withdrawn from the US (2023) and European (2021) markets following a decision by the manufacturer AstraZeneca.